Exposing drug industry funding of UK patient organisations
Open Access
- 22 May 2019
- Vol. 365, l1806
- https://doi.org/10.1136/bmj.l1806
Abstract
Drug company payment disclosures have limited transparency, but Piotr Ozieranski and colleagues find that they are increasing in value and are targeted at select patient organisationsThis publication has 33 references indexed in Scilit:
- The Big Society in an age of austerity: threats and opportunities for Health Consumer and Patients' Organizations in EnglandHealth Expectations, 2014
- Regulating drug information in Europe: a pyrrhic victory for pharmaceutical industry critics?Sociology of Health & Illness, 2012
- Patient Organizations’ Funding from Pharmaceutical Companies: Is Disclosure Clear, Complete and Accessible to the Public? An Italian SurveyPLOS ONE, 2012
- Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure PracticesAmerican Journal of Public Health, 2011
- Patient Groups and the Construction of the Patient-Consumer in Britain: An Historical OverviewJournal of Social Policy, 2010
- In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UKSociology of Health & Illness, 2008
- Health consumer and patients' organizations in Europe: towards a comparative analysisHealth Expectations, 2008
- Should patient groups accept money from drug companies? YesBMJ, 2007
- Should patient groups accept money from drug companies? NoBMJ, 2007
- How NICE may be outflankedBMJ, 2006